243 related articles for article (PubMed ID: 24075920)
21. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
[TBL] [Abstract][Full Text] [Related]
22. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
[TBL] [Abstract][Full Text] [Related]
23. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
24. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.
Aichinger G; Grohmann-Izay B; van der Velden MV; Fritsch S; Koska M; Portsmouth D; Hart MK; El-Amin W; Kistner O; Barrett PN
Clin Vaccine Immunol; 2015 Jan; 22(1):46-55. PubMed ID: 25355797
[TBL] [Abstract][Full Text] [Related]
26. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old.
Keitel WA; Treanor JJ; El Sahly HM; Gilbert A; Meyer AL; Patriarca PA; Cox MM
Vaccine; 2009 Dec; 28(2):379-85. PubMed ID: 19879222
[TBL] [Abstract][Full Text] [Related]
27. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial.
Arakane R; Nakatani H; Fujisaki E; Takahama A; Ishida K; Yoshiike M; Nakayama T; Takeshita F
Vaccine; 2015 Nov; 33(46):6340-50. PubMed ID: 26431983
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.
Cox RJ; Pedersen G; Madhun AS; Svindland S; Sævik M; Breakwell L; Hoschler K; Willemsen M; Campitelli L; Nøstbakken JK; Weverling GJ; Klap J; McCullough KC; Zambon M; Kompier R; Sjursen H
Vaccine; 2011 Oct; 29(45):8049-59. PubMed ID: 21864624
[TBL] [Abstract][Full Text] [Related]
31. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
[TBL] [Abstract][Full Text] [Related]
33. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza.
Kung HC; Huang KC; Kao TM; Lee YC; Chang FY; Wang NC; Liu YC; Lee WS; Liu HJ; Chen CI; Chen CH; Huang LM; Hsieh SM
Vaccine; 2010 Oct; 28(45):7337-43. PubMed ID: 20817013
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults.
Chichester JA; Jones RM; Green BJ; Stow M; Miao F; Moonsammy G; Streatfield SJ; Yusibov V
Viruses; 2012 Nov; 4(11):3227-44. PubMed ID: 23202523
[TBL] [Abstract][Full Text] [Related]
35. Response to a monovalent 2009 influenza A (H1N1) vaccine.
Greenberg ME; Lai MH; Hartel GF; Wichems CH; Gittleson C; Bennet J; Dawson G; Hu W; Leggio C; Washington D; Basser RL
N Engl J Med; 2009 Dec; 361(25):2405-13. PubMed ID: 19745216
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
Heldens JG; Glansbeek HL; Hilgers LA; Haenen B; Stittelaar KJ; Osterhaus AD; van den Bosch JF
Vaccine; 2010 Nov; 28(51):8125-31. PubMed ID: 20950729
[TBL] [Abstract][Full Text] [Related]
37. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
Hatz C; Cramer JP; Vertruyen A; Schwarz TF; von Sonnenburg F; Borkowski A; Lattanzi M; Hilbert AK; Cioppa GD; Leroux-Roels G
Vaccine; 2012 Jul; 30(32):4820-7. PubMed ID: 22626675
[TBL] [Abstract][Full Text] [Related]
38. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.
Clegg CH; Roque R; Perrone LA; Rininger JA; Bowen R; Reed SG
PLoS One; 2014; 9(2):e88979. PubMed ID: 24551202
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study.
Brooks WA; Chang LJ; Sheng X; Hopfer R;
Vaccine; 2015 Aug; 33(36):4610-7. PubMed ID: 26143615
[TBL] [Abstract][Full Text] [Related]
40. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
Treanor JJ; Schiff GM; Couch RB; Cate TR; Brady RC; Hay CM; Wolff M; She D; Cox MM
J Infect Dis; 2006 May; 193(9):1223-8. PubMed ID: 16586358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]